Yield10 Bioscience Signs Research License Agreement Covering CRISPR-Cas9 Genome-Editing Technology with the Broad Institute and Pioneer
August 08, 2018 08:30 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food...
Genome Editing Market to grow at 14% CAGR and exceed $7.5 billion by 2024: Global Market Insights, Inc.
August 10, 2017 07:30 ET
|
Global Market Insights, Inc
Ocean View, Delaware, Aug. 10, 2017 (GLOBE NEWSWIRE) -- The Industry Analysis report “Gene Editing Market By Technology (CRISPR/Cas9, Zinc Finger Nucleases (ZFNs), Meganucleases, TALENS), By...
Yield10 Bioscience Submits “Am I Regulated?” Letter to USDA-APHIS BRS for Genome-Edited Camelina
June 15, 2017 08:45 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., June 15, 2017 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) announced today that it has submitted an “Am I Regulated?” letter to USDA-APHIS’s Biotechnology Regulatory...
Editas Medicine Announces Agreement with Cystic Fibrosis Foundation Therapeutics to Advance New CRISPR/Cas9 Medicines
May 16, 2016 07:30 ET
|
Editas Medicine, Inc.
CAMBRIDGE, Mass., May 16, 2016 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced a three-year agreement with Cystic Fibrosis Foundation...